

Jean L Koff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9294888/publications.pdf>

Version: 2024-02-01

45
papers

1,617
citations

623188

14
h-index

315357

38
g-index

45
all docs

45
docs citations

45
times ranked

3559
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	13.5	804
2	A Time to Kill: Targeting Apoptosis in Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 2942-2955.	1.8	226
3	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
4	PI3K/Î³ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022, 139, 523-537.	0.6	56
5	Targeting the B cell receptor pathway in non-Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 513-522.	1.9	46
6	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 2.	2.8	29
7	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	0.6	28
8	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
9	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
10	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
11	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018, 124, 2327-2336.	2.0	20
12	Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 973-982.	2.0	18
13	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	1.0	18
14	To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 244-255.	1.2	15
15	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2020, 126, 3493-3503.	2.0	15
16	Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e312-e320.	0.2	13
17	Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. <i>Southern Medical Journal</i> , 2016, 109, 606-614.	0.3	13
18	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12

#	ARTICLE	IF	CITATIONS
19	Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology</i> , 2016, 41, 139-151.	0.8	12
20	Effective management strategies for patients with marginal zone lymphoma. <i>Future Oncology</i> , 2018, 14, 1213-1222.	1.1	11
21	Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. <i>Leukemia and Lymphoma</i> , 2018, 59, 888-895.	0.6	11
22	Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. <i>Cancer</i> , 2017, 123, 3222-3225.	2.0	10
23	Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER Medicare Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e115-e121.	0.2	10
24	Insurance status impacts overall survival in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3225-3234.	0.6	10
25	Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1844-1855.	1.1	10
26	Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies. <i>Discovery Medicine</i> , 2016, 21, 181-8.	0.5	9
27	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
28	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	1.0	8
29	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	0.6	7
30	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
31	Cirtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	5
32	Emerging treatments in Castleman disease – a critical appraisal of siltuximab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 9.	3.0	4
33	Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 699-708.e5.	0.2	4
34	Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 239-243.	0.2	4
35	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. <i>Blood</i> , 2016, 128, 1087-1087.	0.6	4
36	Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?. <i>Cancer</i> , 2019, 125, 838-842.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
38	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	0.6	1
39	ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis. <i>Blood</i> , 2021, 138, 2403-2403.	0.6	1
40	Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 3748-3748.	2.0	0
41	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 234-243.e10.	0.2	0
42	Use of Metabolic Tumor Volume (MTV) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 5321-5321.	0.6	0
43	A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication. <i>Blood</i> , 2021, 138, 50-50.	0.6	0
44	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 2398-2398.	0.6	0
45	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	0.6	0